Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · LISATA THERAPEUTICS, INC. (LSTA)

Lisata Therapeutics appoints CFO Jeffrey Farrow to board, expanding it to eight members

Neutral Impact 2 of 5 leadership Written later

Lisata Therapeutics' board increased its size from seven to eight members and appointed Jeffrey Farrow, currently CFO and Chief Strategy Officer of Tarsus Pharmaceuticals, to fill the new seat effective October 13, 2026. Mr. Farrow also joined the Audit Committee, and the board determined he is independent under Nasdaq listing rules.

Key points

  • Appointed effective October 13, 2026 as a Class III director, with an initial term expiring at the 2028 annual meeting
  • Joins the Audit Committee; the board determined he is independent under Nasdaq Capital Market listing rules
  • Has been CFO and Chief Strategy Officer of Tarsus Pharmaceuticals since April 2023 and previously served as CFO of Global Blood Therapeutics until its acquisition by Pfizer in December 2022

The filing

CompanyLISATA THERAPEUTICS, INC. (LSTA)
Form8-K, current report
Filed with the SECOct 14, 2026, 4:25 PM ET
Accession number0001140361-26-039602

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:51 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 14, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.